Bruker (1BRKR) Stock Overview
Develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
1BRKR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Bruker Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.61 |
| 52 Week High | US$44.71 |
| 52 Week Low | US$25.97 |
| Beta | 1.19 |
| 1 Month Change | -12.90% |
| 3 Month Change | -19.51% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -6.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1BRKR | IT Life Sciences | IT Market | |
|---|---|---|---|
| 7D | -2.5% | -7.0% | -6.4% |
| 1Y | n/a | -10.8% | 14.0% |
Return vs Industry: Insufficient data to determine how 1BRKR performed against the Italian Life Sciences industry.
Return vs Market: Insufficient data to determine how 1BRKR performed against the Italian Market.
Price Volatility
| 1BRKR volatility | |
|---|---|
| 1BRKR Average Weekly Movement | 9.4% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IT Market | 7.5% |
| 10% least volatile stocks in IT Market | 2.7% |
Stable Share Price: 1BRKR's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: 1BRKR's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1960 | 11,085 | Frank Laukien | www.bruker.com |
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions.
Bruker Corporation Fundamentals Summary
| 1BRKR fundamental statistics | |
|---|---|
| Market cap | €4.81b |
| Earnings (TTM) | -€19.38m |
| Revenue (TTM) | €2.96b |
Is 1BRKR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1BRKR income statement (TTM) | |
|---|---|
| Revenue | US$3.44b |
| Cost of Revenue | US$1.79b |
| Gross Profit | US$1.65b |
| Other Expenses | US$1.67b |
| Earnings | -US$22.50m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 47.95% |
| Net Profit Margin | -0.65% |
| Debt/Equity Ratio | 73.7% |
How did 1BRKR perform over the long term?
See historical performance and comparisonDividends
Does 1BRKR pay a reliable dividends?
See 1BRKR dividend history and benchmarks| Bruker dividend dates | |
|---|---|
| Ex Dividend Date | Mar 20 2026 |
| Dividend Pay Date | Apr 07 2026 |
| Days until Ex dividend | 10 days |
| Days until Dividend pay date | 28 days |
Does 1BRKR pay a reliable dividends?
See 1BRKR dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/09 19:05 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bruker Corporation is covered by 27 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |